ENTITY
BeiGene

BeiGene (6160 HK)

327
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullishBeiGene
15 Nov 2024 01:38Broker

BeiGene (BGNE US) - Growing Non-GAAP Profit

Strong product sales. In 3Q24, BeiGene recorded product sales of US$993mn (+8% QoQ, +67% YoY). The 9M24 total product sales reached US$2.66bn,...

Logo
105 Views
Share
bullishBeiGene
14 Nov 2024 08:55

BeiGene (6160.HK/​BGNE.US) 24Q3 - Things Are on Track Despite BRUKINSA’s Disappointing QoQ Growth

​BRUKINSA's QoQ growth slowed in 24Q3, but still outperformed peers.Full-year revenue forecast adjusted to $3.7 billion.Peak sales projected at...

Logo
218 Views
Share
bullishBeiGene
12 Aug 2024 08:55

BeiGene (6160.HK/BGNE.US) 24Q2 - It Is Time to Open a New Chapter in China's Pharmaceutical Industry

​BeiGene's strong Q2 results make breakeven possible in Q4.BRUKINSA may surpass Calquence in sales next year.BeiGene is a new king in China's...

Logo
267 Views
Share
bullishBeiGene
10 Aug 2024 05:54Broker

BeiGene (BGNE US) - Sales Exceeding Expectations and Achieving Non-GAAP Profitability

Product sales continued beating expectations. In 2Q24, BeiGene recorded total product sales of US$921mn (+23% QoQ, +66% YoY).

Logo
317 Views
Share
bullishBeiGene
13 May 2024 08:55

BeiGene (6160.HK/​BGNE.US/688235.CH) 24Q1- A Breakeven Point Is on the Horizon, but It Is Not Stable

​BeiGene's high product revenue growth in 24Q1 narrowed net loss, with potential for breakeven in 24Q4.This is an affirmation for BeiGene....

Logo
274 Views
Share
x